Clinical Significance of Detection of ZIC1 Promoter Methylation in Peripheral Blood and Cancer Tissues of Non-small Cell Lung Cancer Patients
10.3971/j.issn.1000-8578.2021.20.0911
- VernacularTitle:非小细胞肺癌患者外周血和肺癌组织中ZIC1启动子甲基化检测的临床意义
- Author:
Yao XU
1
;
Shiguo LIU
;
Chang ZHANG
;
Li ZHANG
;
Shan JIANG
;
Junxia ZHANG
;
Li PENG
Author Information
1. Department of Laboratory, The Third People's Hospital of Hubei Province, Wuhan 430033, China
- Publication Type:Research Article
- Keywords:
ZIC1 methylation;
MSP;
Non-small cell lung cancer;
Lung cancer tissue
- From:
Cancer Research on Prevention and Treatment
2021;48(4):354-357
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the methylation status of ZIC1 gene in peripheral blood and lung cancer tissues of NSCLC patients and its prognostic significance. Methods We took the peripheral blood, cancer tissues and adjacent tissues of 95 NSCLC patients. The peripheral blood of 95 healthy people was taken as control group. MSP was used to compare the detection rate of ZIC1 methylation between peripheral blood and cancer tissues. And we analyzed the correlation of ZIC1 methylation in peripheral blood and cancer tissues with the clinicopathological factors of NSCLC patients. Results The methylation detection rates of ZIC1 in peripheral blood and lung cancer tissues in NSCLC patients were significantly higher than those in peripheral blood of healthy people and adjacent tissues of NSCLC patients (P < 0.05), and the sensitivity and specificity of ZIC1 methylation in the diagnosis of tumor tissues were higher. The positive rate of ZIC1 gene methylation in peripheral blood and tumor tissues of NSCLC patients was significantly correlated with tumor diameter, metastasis, stage and pleural effusion (P < 0.05). Conclusion The methylation of ZIC1 gene is related to the occurrence, development, metastasis and stage of NSCLC. It may be used as a diagnostic and prognostic indicator of NSCLC.
